Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
UKK18ES9TF
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
5-HYDROXYTRYPTAMINE RECEPTOR 1A
Common Name
English  
SEROTONIN RECEPTOR 1A
Common Name
English  
G-21
Common Name
English  
ADRBRL1
Common Name
English  
ADRB2RL1
Common Name
English  
5-HT1A
Common Name
English  
Code System Code Type Description Access References
FDA UNII
UKK18ES9TF
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PRIMARY
PHAROS
P08908
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PRIMARY
UNIPROT
P08908
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PRIMARY
From To
1_109 1_187
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_10
N 1_11
N 1_24
Related Record Type Details Access References
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 22:14:17 EDT 2021 , Edited by admin on Wed Aug 04 22:14:17 EDT 2021
PARTIAL AGONIST->TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
AGONIST
Ki
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
ACTIVATOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
SELECTIVE
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:18 EDT 2021 , Edited by admin on Wed Aug 04 22:14:18 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:19 EDT 2021 , Edited by admin on Wed Aug 04 22:14:19 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:14:16 EDT 2021 , Edited by admin on Wed Aug 04 22:14:16 EDT 2021
Name Property Type Amount Referenced Substance Defining Parameters Access References
MOL_WEIGHT CHEMICAL
0
Created Wed Aug 04 22:14:11 EDT 2021
Created By admin
Last Edited Wed Aug 04 22:14:11 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:31:26 EDT 2017
2 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
3 Megens, A. A., et al. "Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)." Journal of Pharmacology and Experimental Therapeutics 260.1 (1992): 146-159. JA
4 Jensen, Niels H., et al. "N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT 1A agonist, as a putative mediator of quetiapine's antidepressant activity." Neuropsychopharmacology 33.10 (2008): 2303-2312. JA
5 Rickli, Anna, et al. "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens." European Neuropsychopharmacology 26.8 (2016): 1327-1337. JA
6 da Cunha-Bang, Sofi, et al. "Measuring endogenous changes in serotonergic neurotransmission with [11 C] Cimbi-36 positron emission tomography in humans." Translational psychiatry 9.1 (2019): 1-10. JA
7 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
8 MARTINDALE 2011 SRS NOMEN
9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21016_relpax_lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
10 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
11 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
12 Lucot, J. B., et al. "The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors." Experimental brain research 232.8 (2014): 2699-2707. JA POT
13 Kato, Taro, et al. "DSP?1053, a novel serotonin reuptake inhibitor with 5?HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats." Pharmacology Research & Perspectives 3.3 (2015) JA PUBLIC_DOMAIN_RELEASE
14 WIKI WIKI PUBLIC_DOMAIN_RELEASE
15 Lucot, J. B., et al. "The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors." Experimental brain research 232.8 (2014): 2699-2707. JA POT
16 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
17 DeLarge, Alyssa F., Laura L. Erwin, and Peter J. Winsauer. "Atypical binding at dopamine and serotonin transporters contribute to the discriminative stimulus effects of mephedrone." Neuropharmacology 119 (2017): 62-75. JA
18 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
19 Meltzer, H. Y., and M. Maes. "Effect of pindolol on hormone secretion and body temperature: partial agonist effects." Journal of neural transmission 103.1-2 (1996): 77-88. JA NOMEN PUBLIC_DOMAIN_RELEASE
20 Newman-Tancredi, A., et al. "Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy." Naunyn-Schmiedeberg's archives of pharmacology 355.6 (1997): 682-688. JA POT
21 http://www.uniprot.org/uniprot/P08908?sort=score SRS NOMEN
22 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
23 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
24 http://www.uniprot.org/uniprot/P08908 SRS NOMEN
25 UNIPROT UNIPROT NOMEN PUBLIC_DOMAIN_RELEASE
26 Lucot, J. B., et al. "The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors." Experimental brain research 232.8 (2014): 2699-2707. JA POT
27 Prakash, Chandra, et al. "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers." Drug metabolism and disposition 26.5 (1998): 448-456. JA PUBLIC_DOMAIN_RELEASE
28 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 22:14:11 EDT 2021